Stage 3B: GFR 44-30

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure (AstraZeneca)

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure Sponsor: CKD & HTN Indication: Alport Syndrome Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure (AstraZeneca) Read More »

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome (Enyo Pharma)

Protocol Name: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome Sponsor: Enyo Pharma Indication: Alport Syndrome Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome (Enyo Pharma) Read More »

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity

Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity Principal Investigator:Bernard Fischbach, MD Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Read More »

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Observational Study Protocol – Fabry Disease Registry Read More »

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease

Protocol Name: Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Read More »

Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria

Protocol Name: Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria Sponsor: Mineralys Indication: Chronic Kidney Disease (CKD) Principal Investigator: Kim Rice, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria Read More »

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication:  Antineutrophil Cytoplasmic

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Sponsor: River 3 Renal Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal) Read More »

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)

Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease Sponsor: Amicus Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus) Read More »

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B) Read More »